Last Updated : February 18, 2020
Details
Generic Name:
elagolix
Project Status:
Not filed
Therapeutic Area:
Moderate to severe pain associated with endometriosis
Manufacturer:
AbbVie Corporation
Brand Name:
Orilissa
Project Line:
Reimbursement Review
Project Number:
NS0011-000
Submission Type:
Non Submission
Fee Schedule:
N/A
Indications:
Moderate to severe pain associated with endometriosis
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : February 18, 2020